Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
SYBX 
Synlogic Inc (SYBX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: SYBX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $1
1 Year Target Price $1
| 0 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -4.72% | Avg. Invested days 25 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 16.96M USD | Price to earnings Ratio - | 1Y Target Price 1 |
Price to earnings Ratio - | 1Y Target Price 1 | ||
Volume (30-day avg) 1 | Beta 0.53 | 52 Weeks Range 0.90 - 1.96 | Updated Date 08/15/2025 |
52 Weeks Range 0.90 - 1.96 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.09 |
Earnings Date
Report Date 2025-08-07 | When - | Estimate - | Actual -0.04 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -11.18% | Return on Equity (TTM) -7.3% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -1900642 | Price to Sales(TTM) 1652.07 |
Enterprise Value -1900642 | Price to Sales(TTM) 1652.07 | ||
Enterprise Value to Revenue 0.35 | Enterprise Value to EBITDA 0.18 | Shares Outstanding 11696100 | Shares Floating 3605607 |
Shares Outstanding 11696100 | Shares Floating 3605607 | ||
Percent Insiders 11.25 | Percent Institutions 64.72 |
Upturn AI SWOT
Synlogic Inc
Company Overview
History and Background
Synlogic, Inc., founded in 2003, is a biotechnology company pioneering the development of Synthetic Biotic medicines. The company leverages its platform to engineer probiotic bacteria to perform specific therapeutic functions within the body. They went public in 2017.
Core Business Areas
- Synthetic Biotic Medicines: Synlogic develops Synthetic Biotic medicines designed to treat metabolic and inflammatory diseases. This involves engineering bacteria to consume or produce specific metabolites, thereby altering disease pathways.
Leadership and Structure
Aoife Brennan, M.B. Ch.B., Ph.D., is the President and Chief Executive Officer. The company has a standard biotechnology organizational structure with research, development, and clinical trial departments.
Top Products and Market Share
Key Offerings
- SYNB1934 (Phenylketonuria - PKU): SYNB1934 is an orally administered Synthetic Biotic medicine being developed for the treatment of PKU. Clinical trials are ongoing. Market share data is unavailable as the product is not yet approved. Competitors developing treatments for PKU include BioMarin Pharmaceutical (BMNM).
- SYNB8802 (Enteric Hyperoxaluria): SYNB8802 is being developed for Enteric Hyperoxaluria. Currently in early clinical trials. Market share data is unavailable as the product is not yet approved.Competitors developing treatments include Allena Pharmaceuticals (ALNA - Delisted).
Market Dynamics
Industry Overview
The biotechnology industry is highly competitive and research-intensive. It is characterized by high risks and potentially high rewards, long development timelines, and stringent regulatory oversight.
Positioning
Synlogic is positioned as a pioneer in the emerging field of Synthetic Biotic medicines. Its competitive advantage lies in its proprietary platform and its focus on developing novel therapies for metabolic and inflammatory diseases.
Total Addressable Market (TAM)
The TAM for metabolic and inflammatory disease treatments is substantial, estimated to be in the billions of dollars annually. Synlogic aims to capture a segment of this market with its innovative Synthetic Biotic approach.
Upturn SWOT Analysis
Strengths
- Proprietary Synthetic Biotic platform
- Novel therapeutic approach
- Experienced management team
- Strong intellectual property portfolio
Weaknesses
- Early-stage development pipeline
- High cash burn rate
- Reliance on clinical trial success
- Limited commercialization experience
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
- Positive clinical trial results
- Regulatory approvals
Threats
- Clinical trial failures
- Competition from existing therapies
- Regulatory hurdles
- Funding challenges
Competitors and Market Share
Key Competitors
- BMNM
- CRIS
- VYNE
Competitive Landscape
Synlogic's Synthetic Biotic platform represents a novel approach. Competitors rely on traditional pharmaceutical or enzyme therapies. Success for Synlogic relies on successful clinical data.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been limited due to the company's focus on R&D. Growth is expected to accelerate upon successful commercialization of its Synthetic Biotic medicines.
Future Projections: Future growth is contingent on positive clinical trial outcomes and regulatory approvals. Analyst estimates vary widely, reflecting the inherent uncertainty of biotechnology investments.
Recent Initiatives: Recent initiatives include advancing clinical trials for SYNB1934 and SYNB8802, and exploring partnerships to expand its platform.
Summary
Synlogic is a biotechnology company pioneering Synthetic Biotic medicines, targeting metabolic and inflammatory diseases. Its innovative approach is promising, but its pipeline is early-stage and relies on clinical trial success. Financial performance is driven by R&D, and the company needs continued funding. Investors should monitor clinical data and partnerships closely due to inherent risk. Synlogic's success depends on navigating regulatory hurdles and commercializing its innovative platform.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Company Website
- Analyst Reports
- Industry News
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor. Market share data is based on estimates and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Synlogic Inc
Exchange NASDAQ | Headquaters Winchester, MA, United States | ||
IPO Launch date 2015-10-01 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees 1 | Website https://www.synlogictx.com |
Full time employees 1 | Website https://www.synlogictx.com | ||
Synlogic, Inc., a biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618 for the treatment of phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Winchester, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.